German factory orders dropped for the first time in four months as businesses at home were wary of committing to large investments before uncertainty over trade with the US is resolved https://t.co/PI6taon7mn ...

89% of companies worldwide report that trade uncertainty impacted their immediate hiring decisions in April, though most plan for steady hiring in Q3 Employers in Asia Pacific (29%) lead regional hiring intentions, followed by the Americas (27%), and Europe and the Middle East (19%) Information Technology maintains strongest sector Outlook at 36%, followed by Financials & Real Estate (28%), and Industrials & Materials (26%) Companies that are investing the most in technology report more optimistic hiring p ...

May 30, 2025 05:00 AM GMT US Economics Weekly | North America Trade uncertainty, immigration certainty If IEEPA tariffs are overturned, we think the White House can recreate its current tariff structure using other authority. We revise lower our estimate for immigration. Low immigration will make it harder for the unemployment rate to rise. It also pulls potential growth and the neutral rate lower. Key Takeaways Exhibit 1: Trade policy may be uncertain, but immigration policy is not. Incoming data through A ...

Market Performance - The S&P 500 gained 6.1% in May, marking its best performance since an 8.9% rise in November two years ago [2] Employment and Labor Market - Economists expect a gain of 130,000 in nonfarm payrolls for May, with the unemployment rate remaining steady at 4.2% [5] - Wells Fargo economists indicate that May's employment report will reflect the labor market's response to recent trade uncertainties, with hiring appetite among firms remaining low [6][7] - New job postings on Indeed fell to their lowest level since 2020 in May, and hiring plans among small businesses are near cycle lows [7] Earnings Reports - Broadcom is expected to report a 43% year-over-year increase in profit and nearly 20% growth in revenue, driven by AI-related demand and strong semiconductor positioning [8] - CrowdStrike is anticipated to post EPS of $0.66 on revenue of $1.11 billion, with RBC analysts expressing optimism for software stocks in 2025 [10] Bond Market Concerns - Jamie Dimon warns of a potential crack in the bond market due to rising federal debt, urging the government to take remedial measures [11][12] - Dimon suggests that the timeline for a potential crisis could range from six months to six years [13] EV Market Performance - XPeng reported May deliveries of 33,525 Smart EVs, a 230% year-over-year increase, and a year-to-date total of 162,578 Smart EVs, up 293% [13] - Li Auto delivered 40,856 vehicles, up 16.66% year-over-year, while NIO delivered 23,231 vehicles, a 13.1% year-over-year increase [14] Financial Market Outlook - BofA indicates that financial markets are at a high-stakes inflection point, with risk assets poised for a significant move, either a breakout or a breakdown [16]

Core Viewpoint - Johnson & Johnson (J&J) is facing multiple challenges including declining sales in its MedTech segment, loss of exclusivity for its drug Stelara, and ongoing talc lawsuits, while also navigating a volatile macroeconomic environment [1][2][26] Company Strengths and Weaknesses - J&J's diversified business model is a significant strength, operating through pharmaceuticals and medical devices with over 275 subsidiaries, which helps it withstand economic cycles [4] - The separation of its Consumer Health business into Kenvue allows J&J to focus on its core pharmaceutical and medical device operations [5] Innovative Medicine Unit - J&J's Innovative Medicine unit is experiencing growth, with sales increasing by 4.4% in Q1 2025 despite the loss of exclusivity for Stelara [6] - The company anticipates generating over $57 billion in sales from the Innovative Medicines segment in 2025, with expected growth of 5-7% from 2025 to 2030 [7] - J&J has identified 10 new products with potential peak sales of $5 billion, including cancer drugs and pipeline candidates [8] Patent Expiration and Sales Impact - The loss of U.S. patent exclusivity for Stelara in 2025 is expected to significantly impact sales, which were $10.36 billion in 2024, with a projected decline of 33.7% in Q1 2025 [9][10] - The introduction of biosimilars is anticipated to further erode Stelara's sales throughout 2025 [11] MedTech Segment Challenges - J&J's MedTech sales are facing headwinds, particularly in the Asia Pacific region, with challenges from China's volume-based procurement program and competitive pressures [12][13] - No improvement is expected in the Asia Pacific region for 2025, with ongoing impacts from the VBP program [13] Legal Issues - J&J is dealing with over 62,000 lawsuits related to its talc-based products, which allege that these products contain asbestos [14] - A bankruptcy court recently rejected J&J's proposed plan to settle these lawsuits, forcing the company to revert to traditional legal proceedings [15] Stock Performance and Valuation - J&J's stock has outperformed the industry year-to-date, rising 6.8% compared to a 2.7% decline in the industry [16] - The stock is reasonably priced with a price/earnings ratio of 14.25, slightly below the industry average of 14.79 [19] Future Outlook - J&J considers 2025 a "catalyst year" for growth, expecting operational sales growth to accelerate in the second half of the year [24] - The company has a promising R&D pipeline and has recently made acquisitions to strengthen its market position [25]

Core Viewpoint - Amgen's stock has faced a decline of 10.4% over the past three months, largely attributed to macroeconomic uncertainties and trade tensions [1][2]. Group 1: Market Environment - The stock market has experienced volatility due to President Trump's tariffs and China's retaliatory measures, although a recent deal has eased tensions temporarily [2]. - The uncertainty surrounding tariffs continues to impact economic growth, despite pharmaceuticals being exempt from initial tariffs [3]. Group 2: Company Performance - Amgen's revenues grew by 9% year over year in Q1 2025, driven by increased patient demand for innovative medicines [4]. - The company is facing declining revenues from oncology biosimilars and established products like Enbrel, with competitive pressures affecting sales [5]. - Key revenue drivers include older medicines like Prolia and Repatha, as well as new drugs such as Tavneos and Tezspire, alongside rare disease drugs from the acquisition of Horizon Therapeutics [5]. Group 3: Drug Pipeline and Approvals - Amgen is evaluating several drugs for additional indications, which could enhance revenue growth, with Uplizna recently approved for IgG4-related disease [6][7]. - The company has invested significantly in M&A to diversify its pipeline, including the development of MariTide, a novel obesity treatment [8][10]. - Clinical studies for MariTide have shown promising results, and further studies are ongoing [9][10]. Group 4: Biosimilars and Market Strategy - Amgen launched several new biosimilars in 2025, generating substantial sales, including Wezlana and Pavblu, which contributed to a 35% year-over-year increase in biosimilar sales [13][15]. - The company is actively pursuing additional biosimilar approvals to mitigate the impact of upcoming patent expirations for key drugs [15][16]. Group 5: Financial Outlook - Amgen's stock has outperformed the industry and S&P 500, with a year-to-date increase of 7.3% [18]. - The stock is reasonably valued, trading at a price/earnings ratio of 13.12, lower than the industry average [21]. - Earnings estimates for 2025 and 2026 have seen upward revisions, indicating positive market sentiment [24][26]. Group 6: Long-term Growth Potential - The company is expected to maintain long-term revenue growth driven by strong performance from key drugs and innovative medicines [27]. - Despite initial data from MariTide studies being below expectations, it holds potential as a significant product for Amgen [27].

IEA月报：贸易不确定性预计将对全球经济产生压力，并间接影响石油需求。 ...

Gulf Island Fabrication (GIFI) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to Gulf Island's Conference Call to discuss First Quarter twenty twenty five Results. All participants will be in a listen only mode for the duration of the call. This call is being recorded. At this time, I would like to turn the floor over to Ms. Cindy Cook for opening remarks. Cindy, please go ahead. Speaker1 Thank you, and good afternoon. I would like to welcome everyo ...

Mattel (MAT) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Company Participants Jenn Kettnich - VP - Investor RelationsYnon Kreiz - Chairman & CEOAnthony DiSilvestro - Chief Financial OfficerArpine Kocharian - Executive DirectorStephen Laszczyk - Vice PresidentMegan Clapp - Executive DirectorKylie Cohu - Consumer Equity ResearchAlexander Perry - Director, Equity Research Conference Call Participants Eric Handler - MD & Senior Research AnalystChristopher Horvers - Senior Analyst Operator Ladies and gentleme ...

Thailand Monthly Economic Thailand Monthly Economic Monitor Monitor 22 April 2025 Thailand's economic activity showed mixed signals in February. Steady consumption and strong exports were offset by a sharp contraction in private investment due to rising uncertainty. Goods exports remained a key driver, bolstered by robust shipments to the US and China, in part due to frontloading amid rising global trade uncertainties. However, mounting risks from global trade uncertainty are a concern. The tourism recovery ...